The study of therapeutically active agents that target the acetylcholine muscarinic receptor (mAChR) family have their roots in antiquity. From ancient Egyptians inhaling the muscarinic receptor ...

The five muscarinic acetylcholine receptors (mAChRs) are prototypical class A G protein-coupled receptors (GPCRs). mAChRs regulate many fundamental functions of the central and peripheral nervous ...

The muscarinic receptor agonist xanomeline has antipsychotic properties and is devoid of dopamine receptor–blocking activity but causes cholinergic adverse events. Trospium is a peripherally ...

In November, the Boston-based biotech firm Karuna Therapeutics submitted its new schizophrenia medication, called KarXT, to the US Food and Drug Administration for approval. If the agency gives KarXT ...

Subtle changes in neurotransmission that occur during Alzheimer’s disease have been tough to track in living people. A new positron emission tomography tracer may change that. In the January 12 ...

An international study led by Monash University has, for the first time, harnessed cutting-edge technology to reveal new and unprecedented information of how a special class of drugs, known as ...

Long-acting muscarinic antagonists (LAMAs), as add-on therapy to inhaled corticosteroids, improved peak forced expiratory volume in 1 second (FEV1) and reduced exacerbations in children younger than ...

Key roles in modulating cognition and behavior made the M1 muscarinic acetylcholine receptor (mAChR) a prime target for Alzheimer disease drug developers dating back nearly two decades. However, ...

Sosei Group Corp. has reported clinical development plans by its partner Neurocrine Biosciences Inc. for two new oral muscarinic receptor agonist candidates, NBI-1117569 and NBI-1117567.

When Vima Therapeutics launched last year to take its drug candidate into human testing, the lead indication was isolated dystonia, a neurological movement disorder whose few treatment options leave a ...

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be useful for the treatment of psychiatric ...